Search:
 
This image is of a spacer graphic
NHF Face Book NHF Twitter
+ Login to my NHF
+ NHF Membership
+ Donate to NHF
+ Chapter Center
+ Hechos y Respuestas Rápidas
+ Ethics Advisory Committee
This image is of a spacer graphic
-News
 NHF In The News
 NHF eNotes
 Medical Advisories
 Advocacy and Legislative Updates
-Medical News
 Blood Safety News
 NHF and Community News
 Industry News
 Travel Advisory

 

 

 
FDA and Boehringer Ingelheim Alert Healthcare Professionals to Serious Bleeding
 

The U.S. Food and Drug Administration (FDA) has released a warning letter about Boehringer
Ingelheim Pharmaceuticals’ HIV drug Aptivus®, after several patients experienced bleeding in
the brain. Aptivus® first received FDA approval in June 2005.

In a clinical trial that included 6,840 HIV-infected participants, 13 patients experienced
intracranial bleeding and eight died. In response Boehringer Ingelheim placed a “black box”
warning on all labels for Aptivus®. The paragraph is positioned inside the box to signify the
FDA’s strictest warning. In addition, Boehringer Ingelheim recently sent a letter informing
healthcare professionals of the new safety warning for Aptivus®, mentioning the fatal
intracranial bleeding that has occurred in some patients.       

The FDA and Boehringer Ingelheim have said that while investigations are ongoing, other risk
factors may have played a part in the bleeding-related complications. Patients who have
experienced recent head trauma or neurosurgery, or those taking certain medications such as
anticoagulants or antiplatelet agents, may have been at increased risk for intracranial bleeding.      

Read the “Dear Healthcare Professional” warning letter>>

Read the black box warning label for Aptivus®>>

Source: The Washington Post, June 30, 2006 and The Wall Street Journal, July 3, 2006

 

This section of our Web site is sponsored by: